Panoramica dell'azienda
Cingulate Inc. operates within the healthcare sector, specifically functioning as a biotechnology firm dedicated to developing pharmaceutical products via its proprietary drug delivery platform technology. The company's primary focus is on treating attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States, with its lead product candidate identified as CTx-1301 (dexmethylphenidate). Despite its specialized focus, the company maintains a relatively small operational scale, employing only 14 individuals and holding a market capitalization of $66.98M. The absence of reported annual revenue in the available data indicates that the firm is likely still in a pre-commercialization or early-stage clinical development phase, which is typical for biotechnology entities at this valuation level. This market cap, combined with the lack of revenue generation, suggests the company's current position relies heavily on future clinical outcomes and capital raising rather than existing cash flows from sales. The minimal headcount further underscores the resource-intensive nature of biotechnology development, where significant capital is required for research and trials without a large internal workforce.
Salute finanziaria
The financial statements reveal a net income of $-22,449,912 and an EBITDA of $-19,397,214, while revenue remains unreported in the TTM period. The substantial gap between the reported net income loss and the EBITDA figure highlights significant non-operating expenses, likely driven by stock-based compensation or one-time charges common in early-stage biotech firms. Free cash flow stands at $-10,425,198, indicating that the company is burning cash at a rate that necessitates continuous external financing to sustain operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which is consistent with a company that has not yet generated commercial revenue to establish a profit history. On the balance sheet, the company holds $10.95M in cash against $8.79M in debt, resulting in a debt-to-equity ratio of 350.21. Although the company possesses more liquid assets than debt, the extremely high debt-to-equity ratio suggests a leveraged capital structure relative to its equity base, reflecting the high-risk profile of pre-revenue biotechnology ventures. The current ratio of 1.16 indicates that the company maintains sufficient short-term liquid assets to cover its current liabilities, though the margin is relatively tight for an entity with such high cash burn rates. Return on Equity is reported at -450.6% and Return on Assets at -83.2%, metrics that reveal the company is currently destroying shareholder value and utilizing assets inefficiently in the context of traditional profitability measures.
Valutazione del valore
Valuation multiples for Cingulate Inc. present mixed signals due to the lack of earnings, with a trailing P/E ratio of N/A and a forward P/E of -3.96. The negative forward P/E implies that analysts or the market expects earnings to remain negative or for the company to incur losses in the near term, preventing a meaningful earnings-based valuation. The price-to-book ratio stands at 16.65, suggesting that the market values the company at a significant premium over its book value, likely driven by the potential value of its intellectual property and drug pipeline rather than tangible assets. Since revenue is N/A, the price-to-sales ratio is also N/A, making this traditional metric inapplicable for assessing the company's current multiple expansion relative to sales growth. The EV/EBITDA ratio is calculated at -3.34, which further confirms that earnings-based valuation metrics are not currently applicable for this pre-profitable entity. Regarding price action, the 52-week high is $11.89 and the 52-week low is $3.20; without a specific current price provided in the source data, the trading position relative to this range cannot be precisely quantified, but the wide spread indicates high volatility. The beta of -0.77 is anomalous for a stock, typically ranging between 0.5 and 1.5, and suggests an inverse correlation to the broader market, meaning the stock moves counter to general market trends, adding a unique layer of idiosyncratic risk.
Growth & Income
Reported revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the company's status as a pre-revenue entity with no historical growth trajectory to analyze. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue because neither metric has been established. As the company does not distribute dividends, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm retains all available capital to fund its R&D and clinical trial expenditures. This reinvestment strategy is standard for biotechnology companies in the development phase, where generating a return on investment through product sales is the primary long-term objective rather than providing immediate income to shareholders. The overall growth and income profile is characterized by a complete absence of current income generation and measurable historical growth, with all financial resources directed toward achieving future commercial milestones.